Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Latuda

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Daily Brief: Takeda seals $62bn Shire deal, Autolus IPO, Gottlieb warning

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Shire warms to Takeda’s latest offer, extending deadline

The new offer is £5 per share higher than Takeda’s opening bid

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

- PMLiVE

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

- PMLiVE

Boehringer abandons PDE-targeted Alzheimer’s drug

But will keep testing the candidate in schizophrenia

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links